Drug or treatment
Aumolertinib clinical trials
As of November 12, 2026, Find a Trial lists 4 clinical trials of Aumolertinib that are recruiting, at sites in 5 countries (most in China (2), Taiwan (1), Bosnia and Herzegovina (1)). By phase: Phase 1 (2), Phase 2 (1), Phase 2/3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 5Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Aumolertinib with phased chemotherapy for EGFR L858R lung cancer that has spread | Phase 2 | New Taipei City and 2 other locations | Recruiting | Jun 3, 2026 |
| Aumolertinib for European adults with EGFR‑mutant advanced non‑small cell lung cancer | Phase 1 | Banja Luka and 5 other locations | Recruiting | Aug 19, 2025 |
| Evaluating Aumolertinib's Effect on Midazolam in Lung Cancer Patients | Phase 1 | Hangzhou, Zhejiang | Recruiting | Apr 13, 2025 |
| HS-20117 combined with aumolertinib for advanced EGFR‑mutant non-squamous lung cancer | Phase 2/3 | Tianjin, Tianjin Municipality and 1 other locations | Recruiting | May 16, 2024 |
All recruiting trials (4)
-
Aumolertinib with phased chemotherapy for EGFR L858R lung cancer that has spread
This trial tests whether adding phased chemotherapy to aumolertinib helps people with EGFR L858R–positive metastatic lung adenocarcinoma.
-
Aumolertinib for European adults with EGFR‑mutant advanced non‑small cell lung cancer
This Phase 1 trial tests daily oral aumolertinib in European adults with advanced or metastatic NSCLC that has activating EGFR mutations to see how the drug is processed in the body and whether it is safe and tolerable.
-
Evaluating Aumolertinib's Effect on Midazolam in Lung Cancer Patients
This study is testing how a new lung cancer drug, aumolertinib, affects the way the body processes another medication, midazolam, in patients with advanced non-small cell lung cancer who have specific genetic changes.
-
HS-20117 combined with aumolertinib for advanced EGFR‑mutant non-squamous lung cancer
This tests whether adding the bispecific antibody HS-20117 to aumolertinib helps people with advanced, treatment‑naive, EGFR‑mutant non‑squamous non‑small cell lung cancer live longer or have better tumor control.
Quick answers
How many clinical trials of Aumolertinib are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in China (2 trials), Taiwan (1 trial), Bosnia and Herzegovina (1 trial), Bulgaria (1 trial), Moldova (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 2: 1, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.